SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Investors are intensely focused on NVIDIA's upcoming earnings, which is driving significant volatility and speculation across the semiconductor and broader tech sectors. The community remains deeply divided, with many debating whether the stock will trigger a major breakout or succumb to a 'sell the news' reaction, while traders actively adjust their positions and hedge against potential price swings.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is trending as traders react to a strong quarterly earnings report that beat revenue expectations, bolstered by double-digit revenue growth and a positive outlook for new store openings in the upcoming year. While the community is actively debating the company's premium valuation and its ability to maintain growth in a challenging consumer environment, bullish sentiment remains centered on its aggressive physical expansion and strong brand loyalty.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is trending as investors digest a strong earnings beat and raised full-year guidance that highlights robust demand across AI infrastructure, aerospace, and defense. The community remains actively focused on whether this performance signals a long-term structural uptrend or a temporary order cycle, with many traders discussing potential breakout levels and the stock's role in the broader AI supply chain.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently at the center of intense market speculation and short-seller conflict as investors react to favorable comparative clinical data against major competitors in the bladder cancer space. The community is focused on the strategic impact of securing a reliable BCG supply chain, the potential for label expansion, and the belief that the stock is being heavily manipulated ahead of pending regulatory milestones.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and the online community express intense polarization over the stock's slide to new lows, with heated debates centered on concerns regarding governance, perceived financial mismanagement, and the platform's long-term viability. The conversation is further fueled by high-stakes speculation about potential insider trading and the broader impact of political controversy on company valuation.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silver is experiencing a volatile liquidation phase as investors react to surging bond yields and broader market uncertainty, fueling intense debate between bulls citing structural supply deficits and bears warning of a popped speculative bubble. The community remains deeply divided, with many actively discussing whether this pullback is a temporary consolidation before further gains or the beginning of a prolonged bear market.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is facing sustained downward pressure as investors grow increasingly cautious following leadership changes and a weaker-than-expected outlook, leading the stock to trade near 52-week lows. While many community members remain optimistic about the company's subscription-based model and long-term potential, others are actively debating whether to average down their positions or exit entirely given the consistent price decline and market volatility.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies is trending as investors digest its role as a digital asset treasury holding significant HYPE token reserves, while the community intensely debates its long-term potential versus direct token exposure. Market participants are closely watching the stock's high-volume momentum and its price sensitivity to the broader crypto ecosystem and tokenization trends.

Toll Brothers, Inc. engages in the design, building, marketing, and arranging of financing for detached and attached homes in residential communities. It operates through the following geographical segments: North Region, Mid-Atlantic Region, South Region, Mountain Region, and Pacific Region. The North region segment includes Connecticut, Delaware, Massachusetts, Michigan, New Jersey, New York, and Pennsylvania. The Mid-Atlantic region segment consists of Georgia, Maryland, North Carolina, Tennessee, and Virginia. The South region segment includes Florida, South Carolina, and Texas. The Mountain region segment consists of Arizona, Colorado, Idaho, Nevada, and Utah. The Pacific region segment includes California, Oregon, and Washington. The company was founded by Robert I. Toll, and Bruce E. Toll in May 1967 and is headquartered in Fort Washington, PA.

Toll Brothers Inc.

Toll Brothers is currently trending as investors weigh strong luxury housing demand and solid margins against the broader housing sector's sensitivity to high mortgage rates and shifting inventory levels. The community is actively debating whether the builder's affluent customer base will insulate it from current market headwinds or if persistent macro pressures will ultimately dampen future earnings and deliveries.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is trending following the release of positive initial Phase 2 ReInspire trial data for zovegalisib in patients with PIK3CA-driven vascular anomalies. The community is actively discussing the drug's efficacy and safety profile, alongside ongoing debate regarding the company's competitive positioning in the oncology sector and the impact of recent clinical milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Watching $SYRS closely. SELECT-MDS-1 trial data in Nov could be game-changer. Biotech&#39;s high risk, high reward. Tamibarotene looks promising for HR-MDS patients. Might take a small position if trial results look good. great article: https://beyondspx.com/article/syros-pharmaceuticals-syrs-weathering-the-storm-and-charting-a-path-forward

Joao Carvalho

puppis

Syros Pharmaceuticals was founded in November 2011 with a focus on developing medicines that control the expression of genes to treat cancer and other diseases. The company's proprietary platform technology, known as the Syros Gene Control Platform, has enabled the identification of novel drug targets and the development of small molecule therapeutics that selectively modulate gene expression.

Beyondspx

Syros Pharmaceuticals (SYRS): Weathering the Storm and Charting a Path Forward

StockTwits Web

Syros Pharmaceuticals Inc.

 closely. SELECT-MDS-1 trial data in Nov could be game-changer. Biotech's high risk, high reward. Tamibarotene looks promising for HR-MDS patients. Might take a small position if trial results look good. great article: 

Mike

@NVDAMillionaire how do you do to watch this closely? I wrote and ask them for some guidance but no replay!

 how do you do to watch this closely? I wrote and ask them for some guidance but no replay!